All News

pso.PsA_.NPF_.jpg

Updates in Psoriatic Arthritis at EULAR 2022

Antoni Chan, MD, PhD

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.

Read Article
PSS.scleroderma.arthritis.contractures

Immune Checkpoint Inhibitor Associated Arthritis

Jack Cush, MD

Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

Read Article
xray-of-hands-1526780.jpg

Bridge Prednisone Use Fails to Improve Outcomes

Jack Cush, MD

A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.

Read Article
RNL22 RA Best Management

RNL 2022: Rheumatoid Arthritis - Best Management

Jack Cush, MD

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Read Article
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Read Article
coronavirus,COVID,Mask,red

Increasing Corticosteroid Use in Non-Hospitalized COVID-19

Jack Cush, MD

JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.

Read Article
dementia,brain

Is Gout Protective Against Dementia?

MedPage Today

People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.

Read Article
Low rates of hypersensitivity reactions (HSR) to #anifrolumab Pooled data MUSE & TULIP-1/-2 w/1100 pts: 👉1 anaphylaxis (0.15%) 👉12 HSR (3%) 👉43 infusion reaction (9%): N/V/headache 👉most easily treatable w/antihistamine, GCs, acetaminophen #EULAR2022 POS0708 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Janet Pope Janetbirdope ( View Tweet)
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those: 💠SLEDAI=>10 💠dsDNA+ve + ⬇️C3 and/ ⬇️C4 💠⬇️C3 and/ C4 pre-treatment 💠Response high regardless SDI, Steroid, #lupus duration @RheumNow https://t.co/fLggazbRQu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

Links:

Richard Conway RichardPAConway ( View Tweet)
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

Links:

Richard Conway RichardPAConway ( View Tweet)
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186: 👉no unexpected AEs; rate of AEs⬇️over time 👉COVID19 seen in 12 controls, 7 VCS 👉4 deaths w/control arm vs 0 deaths w/ VCS 👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

Immune Checkpoint Inhibitor Associated Arthritis Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Retrospective pregnancy outcome study in 154 Rheumatic pts. Systemic sclerosis pts had higher risk of adverse preg outcomes (vs HC - 60.6% vs 10.0%; OR = 14; SSc had increase in 1st trimester miscarriage, preeclampsia, SGA & Preterm https://t.co/hfd6SsCRmr Conclusions

Links:

Dr. John Cush RheumNow ( View Tweet)

Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011, Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation... https://t.co/u86Vd8bFGr #MedEdTwitter https://t.co/IpKqPoWM9R

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Adherence to Rheumatoid Therapies Dr. Michaud presents Adherence to Rheumatoid Therapies at the RheumNow Live 2022 meeting held in March. #MedEd https://t.co/sCCnx82ptN https://t.co/GJE0Ktwm7B

Links:

Dr. John Cush RheumNow ( View Tweet)
Amitriptyline and FDA Treatments for Fibromyalgia #MedEd https://t.co/9PylojjL4S https://t.co/TxErjtU4eE

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×